select

Goldfrank’s Toxicologic Emergencies, 9e
Lewis S. Nelson, Neal A. Lewin, Mary Ann Howland, Robert S. Hoffman, Lewis R. Goldfrank, Neal E. Flomenbaum

Preface    Copyright    Contributors

 
 Table of Antidotes in Depth
Chapter 1Historical Principles and Perspectives
Chapter 2Toxicologic Plagues and Disasters in History
 
Part A. The General Approach to Medical Toxicology
Chapter 3Initial Evaluation of the Patient: Vital Signs and Toxic Syndromes
Chapter 4Principles of Managing the Acutely Poisoned or Overdosed Patient
Chapter 5Diagnostic Imaging
Chapter 6Laboratory Principles
Chapter 7Techniques Used to Prevent Gastrointestinal Absorption
 Antidotes in Depth (A1): Syrup of Ipecac
 Antidotes in Depth (A2): Activated Charcoal
 Antidotes in Depth (A3): Whole-Bowel Irrigation and Other Intestinal Evacuants
Chapter 8Pharmacokinetic and Toxicokinetic Principles
Chapter 9Principles and Techniques Applied to Enhance Elimination
Chapter 10Use of the Intensive Care Unit
 
Part B. The Fundamental Principles of Medical Toxicology
Section 1. Biochemical and Metabolic Principles
Chapter 11Chemical Principles
Chapter 12Biochemical and Metabolic Principles
Chapter 13Neurotransmitters and Neuromodulators
Chapter 14Withdrawal Principles
 
Section 2. Pathophysiologic Basis: Organ Systems
Chapter 15Thermoregulatory Principles
Chapter 16Fluid, Electrolyte, and Acid–Base Principles
Chapter 17Psychiatric Principles
Chapter 18Neurologic Principles
Chapter 19Ophthalmic Principles
Chapter 20Otolaryngologic Principles
Chapter 21Respiratory Principles
Chapter 22Electrophysiologic and Electrocardiographic Principles
Chapter 23Hemodynamic Principles
Chapter 24Hematologic Principles
Chapter 25Gastrointestinal Principles
Chapter 26Hepatic Principles
Chapter 27Renal Principles
Chapter 28Genitourinary Principles
Chapter 29Dermatologic Principles
 
Section 3. Special Populations
Chapter 30Reproductive and Perinatal Principles
Chapter 31Pediatric Principles
Chapter 32Geriatric Principles
Chapter 33Postmortem Toxicology
 Special Considerations (SC1): Organ Procurement from Poisoned Patients
 
Part C. The Clinical Basis of Medical Toxicology
Section 1
A. Analgesics and Antiinflammatory Medications
Chapter 34Acetaminophen
 Antidotes in Depth (A4): N-Acetylcysteine
Chapter 35Salicylates
 Antidotes in Depth (A5): Sodium Bicarbonate
Chapter 36Nonsteroidal Antiinflammatory Drugs
Chapter 37Colchicine, Podophyllin and the Vinca Alkaloids
 Special Considerations (SC2): Intrathecal Administration of Xenobiotics
Chapter 38Opioids
 Antidotes in Depth (A6): Opioid Antagonists
B. Dietary and Nutritional Xenobiotics
Chapter 39Dieting Agents and Regimens
Chapter 40Iron
 Antidotes in Depth (A7): Deferoxamine
Chapter 41Vitamins
Chapter 42Essential Oils
Chapter 43Herbal Preparations
Chapter 44Athletic Performance Enhancers
Chapter 45Food Poisoning
Chapter 46Botulism
 Antidotes in Depth (A8): Botulinum Antitoxin
C. Pharmaceuticals
Chapter 47Anticonvulsants
 Antidotes in Depth (A9): L-Carnitine
Chapter 48Antidiabetics and Hypoglycemics
 Antidotes in Depth (A10): Dextrose
 Antidotes in Depth (A11): Octreotide
Chapter 49Thyroid and Antithyroid Medications
Chapter 50Antihistamines and Decongestants
 Antidotes in Depth (A12): Physostigmine Salicylate
Chapter 51Antimigraine Medications
Chapter 52Antineoplastics Overview
Chapter 53Antineoplastics: Methotrexate
 Antidotes in Depth (A13): Leucovorin (Folinic Acid) and Folic Acid
 Antidotes in Depth (A14): Glucarpidase (Carboxypeptidase G2)
 Special Considerations (SC3): Extravasation of Xenobiotics
Chapter 54Miscellaneous Antineoplastics
Chapter 55Pharmaceutical Additives
D. Antimicrobials
Chapter 56Antibacterials, Antifungals, and Antivirals
Chapter 57Antituberculous Medications
 Antidotes in Depth (A15): Pyridoxine
Chapter 58Antimalarials
E. Cardiopulmonary Medications
Chapter 59Anticoagulants
 Antidotes in Depth (A16): Vitamin K1
 Antidotes in Depth (A17): Protamine
Chapter 60Calcium Channel Blockers
 Antidotes in Depth (A18): Insulin-Euglycemia Therapy
Chapter 61-Adrenergic Antagonists
 Antidotes in Depth (A19): Glucagon
Chapter 62Other Antihypertensives
Chapter 63Antidysrhythmics
Chapter 64Cardioactive Steroids
 Antidotes in Depth (A20): Digoxin-Specific Antibody Fragments
Chapter 65Methylxanthines and Selective 2 Adrenergic Agonists
F. Anesthetics and Related Medications
Chapter 66Local Anesthetics
 Antidotes in Depth (A21): Intravenous Fat Emulsions
Chapter 67Inhalational Anesthetics
Chapter 68Neuromuscular Blockers
 Antidotes in Depth (A22): Dantrolene Sodium
G. Psychotropic Medications
Chapter 69Antipsychotics
Chapter 70Lithium
Chapter 71Monoamine Oxidase Inhibitors
Chapter 72Serotonin Reuptake Inhibitors and Atypical Antidepressants
Chapter 73Cyclic Antidepressants
Chapter 74Sedative-Hypnotics
 Antidotes in Depth (A23): Flumazenil
H. Substances of Abuse
Chapter 75Amphetamines
Chapter 76Cocaine
 Special Considerations (SC4): Internal Concealment of Xenobiotics
 Antidotes in Depth (A24): Benzodiazepines
Chapter 77Ethanol
 Antidotes in Depth (A25): Thiamine Hydrochloride
Chapter 78Ethanol Withdrawal
Chapter 79Disulfiram and Disulfiram-Like Reactions
Chapter 80-Hydroxybutyric Acid
Chapter 81Inhalants
Chapter 82Hallucinogens
Chapter 83Cannabinoids
Chapter 84Nicotine
Chapter 85Phencyclidine and Ketamine
I. Metals
Chapter 86Aluminum
Chapter 87Antimony
Chapter 88Arsenic
 Antidotes in Depth (A26): Dimercaprol (British Anti-Lewisite or BAL)
Chapter 89Bismuth
Chapter 90Cadmium
Chapter 91Chromium
Chapter 92Cobalt
Chapter 93Copper
Chapter 94Lead
 Antidotes in Depth (A27): Succimer (2,3-Dimercaptosuccinic Acid)
 Antidotes in Depth (A28): Edetate Calcium Disodium (CaNa2EDTA)
Chapter 95Manganese
Chapter 96Mercury
Chapter 97Nickel
Chapter 98Selenium
Chapter 99Silver
Chapter 100Thallium
 Antidotes in Depth (A29): Prussian Blue
Chapter 101Zinc
J. Household Products
Chapter 102Antiseptics, Disinfectants, and Sterilants
Chapter 103Camphor and Moth Repellents
Chapter 104Caustics
Chapter 105Hydrofluoric Acid and Fluorides
 Antidotes in Depth (A30): Calcium
Chapter 106Hydrocarbons
Chapter 107Toxic Alcohols
 Special Considerations (SC5): Diethylene Glycol
 Antidotes in Depth (A31): Fomepizole
 Antidotes in Depth (A32): Ethanol
K. Pesticides
Chapter 108Pesticides: An Overview of Rodenticides and a Focus on Principles
Chapter 109Barium
Chapter 110Sodium Monofluoroacetate and Fluoroacetamide
Chapter 111Phosphorus
Chapter 112Strychnine
Chapter 113Insecticides: Organic Phosphorus Compounds and Carbamates
 Antidotes in Depth (A33): Pralidoxime
 Antidotes in Depth (A34): Atropine
Chapter 114Insecticides: Organic Chlorines, Pyrethrins/Pyrethroids, and Insect Repellents
Chapter 115Herbicides
Chapter 116Methyl Bromide and Other Fumigants
L. Natural Toxins and Envenomations
Chapter 117Mushrooms
Chapter 118Plants
Chapter 119Arthropods
 Antidotes in Depth (A35): Antivenom (Scorpion and Spider)
Chapter 120Marine Envenomations
Chapter 121Snakes and Other Reptiles
 Antidotes in Depth (A36): Antivenom (Crotaline)
M. Occupational and Environmental Toxins
Chapter 122Industrial Poisoning: Information and Control
Chapter 123Nanotoxicology
Chapter 124Simple Asphyxiants and Pulmonary Irritants
Chapter 125Carbon Monoxide
 Antidotes in Depth (A37): Hyperbaric Oxygen
Chapter 126Cyanide and Hydrogen Sulfide
 Antidotes in Depth (A38): Sodium and Amyl Nitrite
 Antidotes in Depth (A39): Sodium Thiosulfate
 Antidotes in Depth (A40): Hydroxocobalamin
Chapter 127Methemoglobin Inducers
 Antidotes in Depth (A41): Methylene Blue
Chapter 128Smoke Inhalation
N. Disaster Preparedness
Chapter 129Risk Assessment and Risk Communication
Chapter 130Hazmat Incident Response
Chapter 131Chemical Weapons
Chapter 132Biological Weapons
Chapter 133Radiation
 Antidotes in Depth (A42): Potassium Iodide
 Antidotes in Depth (A43): DTPA [Pentetic Acid or Pentetate (Zinc or Calcium) Trisodium]
 
Section 2. Poison Centers and Epidemiology
Chapter 134Poison Prevention and Education
Chapter 135Poison Centers and Poison Epidemiology
Chapter 136International Perspectives on Medical Toxicology
Chapter 137Principles of Epidemiology and Research Design
Chapter 138Adverse Drug Events and Postmarketing Surveillance
Chapter 139Medication Safety and Adverse Drug Events
Chapter 140Risk Management and Legal Principles